CN117752776B - Pharmaceutical preparation and application thereof in preparation of drugs for treating stress injury of Babylonia after transportation - Google Patents
Pharmaceutical preparation and application thereof in preparation of drugs for treating stress injury of Babylonia after transportation Download PDFInfo
- Publication number
- CN117752776B CN117752776B CN202410194760.4A CN202410194760A CN117752776B CN 117752776 B CN117752776 B CN 117752776B CN 202410194760 A CN202410194760 A CN 202410194760A CN 117752776 B CN117752776 B CN 117752776B
- Authority
- CN
- China
- Prior art keywords
- agent
- parts
- babylonia
- stress injury
- transportation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000606434 Babylonia Species 0.000 title claims abstract description 74
- 230000006378 damage Effects 0.000 title claims abstract description 50
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 44
- 208000014674 injury Diseases 0.000 title claims abstract description 44
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 18
- 229940079593 drug Drugs 0.000 title description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 99
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 claims abstract description 17
- 229960003760 florfenicol Drugs 0.000 claims abstract description 17
- 229960005404 sulfamethoxazole Drugs 0.000 claims abstract description 17
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims abstract description 17
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims abstract description 16
- 108010015776 Glucose oxidase Proteins 0.000 claims abstract description 16
- 239000004366 Glucose oxidase Substances 0.000 claims abstract description 16
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000010081 allicin Nutrition 0.000 claims abstract description 16
- 229940076810 beta sitosterol Drugs 0.000 claims abstract description 16
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 16
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940116332 glucose oxidase Drugs 0.000 claims abstract description 16
- 235000019420 glucose oxidase Nutrition 0.000 claims abstract description 16
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims abstract description 16
- 229950005143 sitosterol Drugs 0.000 claims abstract description 16
- 108010008488 Glycylglycine Proteins 0.000 claims abstract description 15
- 229940043257 glycylglycine Drugs 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 5
- 239000004576 sand Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000012136 culture method Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000000903 blocking effect Effects 0.000 abstract description 6
- 230000000857 drug effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 33
- 241000237858 Gastropoda Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000010586 diagram Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 241000723298 Dicentrarchus labrax Species 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 241000585116 Galba truncatula Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 241000237852 Mollusca Species 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000012364 cultivation method Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000920062 Babylonia areolata Species 0.000 description 1
- 241000920060 Babylonia formosae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001522722 Buccinidae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000243714 Lutosa Species 0.000 description 1
- 241000238003 Neogastropoda Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 238000001792 White test Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical group N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 239000009383 gan-kang Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical preparation. The pharmaceutical formulation comprises: agent A and agent B; the agent A comprises the following components in parts by weight: 8-15 parts of florfenicol and 6-14 parts of sulfamethoxazole; the agent B comprises the following components: 10-20 parts of allicin, 5-8 parts of glucose oxidase, 2-4 parts of beta-sitosterol and 1-3 parts of glycylglycine. In addition, the invention also claims the application of the pharmaceutical preparation in preparing the medicine for treating the stress injury after transportation of the Babylonia. The pharmaceutical preparation provided by the invention adopts the agent A and the agent B to be matched for use, can play a role in synergistically improving the drug effect, has excellent treatment effect and blocking effect on the stress injury of the Babylonia after transportation, and can obviously reduce the incidence rate of the stress injury of the Babylonia.
Description
Technical Field
The invention belongs to the technical field of snail breeding, and in particular relates to a pharmaceutical preparation and application thereof in preparing a medicament for treating stress injury of Babylonia after transportation.
Background
The Babylonia, the aliases of Babylonia, sweet snail, southern snail, yellow snail and flower snail belong to Mollusca (Mollusca), gastropoda (Gastropoda), front gill subclass (Prosobranchia), celloda (Neogastropoda), moth snail (Buccinidae) and Babylonia (Babylonia) and are main cultured shellfish varieties in China. The Babylonia snail meat is fine and smooth, delicious in taste and has the reputation of 'pearl in dish'; it is rich in protein, vitamins, amino acids and trace elements essential to human body, and is a typical natural animal health food with high protein, low fat and high calcium.
The eastern conch breeding or propagation often involves transportation, but eastern conch is easy to generate stress reaction in the transportation process, so that resistance is reduced, the health condition is poor, and the eastern conch cannot be well adapted to a new environment, and disease death is often induced. In addition, the Babylonia is extremely easy to stab the feet of each other and cause violent struggling because of the problems of strong stress, sharp tail, thin shell and the like in the transportation process, so that mechanical damage is caused, and the Babylonia is more difficult to adapt to new environments due to high transportation density and jolting in the way. The mechanical damage can aggravate the stress response of the Babylonia in the transportation process, and further the death of the Babylonia is more easily caused.
Patent CN113812357A discloses a keep-alive transportation method for slowing down oxidation stress damage of sea bass, wherein emulsified herba Melissae axillaris essential oil is added into a transportation water body of a PE bag, the water temperature is controlled at 12 (+ -1) DEGC, the concentration of the herba Melissae axillaris essential oil is respectively 10 mg/L, 20 mg/L and 40mg/L, and the sea bass is kept alive and transported within the concentration range, so that the energy consumption and metabolism rate of the sea bass in the process of keeping-alive and transportation can be reduced; slowing down damage and apoptosis induced by keep-alive transport to gill, liver and kidney tissues; delay the rise of serum cortisol, stress protein, lactic acid, blood sugar and oxidase activity of sea bass; enhancing the total antioxidant capacity of sea bass during transportation. However, the method is difficult to be applied to the cultivation of other aquatic animals, and mechanical external damage is less generated in the sea bass transportation process. Therefore, how to develop more schemes capable of relieving stress injury and suitable for the stress injury after transportation of Babylonia is a technical problem to be solved.
Disclosure of Invention
Aiming at the prior art problems, the primary aim of the invention is to provide a pharmaceutical preparation, wherein the pharmaceutical preparation is prepared by matching an agent A and an agent B, has excellent treatment effect and blocking effect on the stress injury of the Babylonia after transportation, and can remarkably reduce the incidence rate of the stress injury of the Babylonia.
A second object of the present invention is to provide a process for the preparation of a pharmaceutical formulation.
The third object of the invention is to provide an application of a pharmaceutical preparation in preparing a medicament for treating stress injury after transportation of Babylonia.
The fourth object of the invention is to provide a cultivation method of the Babylonia after transportation.
In order to achieve the above object, the present invention is realized by the following technical scheme:
A pharmaceutical formulation comprising: agent A and agent B; the agent A comprises the following components in parts by weight: 8-15 parts of florfenicol and 6-14 parts of sulfamethoxazole; the agent B comprises the following components: 10-20 parts of allicin, 5-8 parts of glucose oxidase, 2-4 parts of beta-sitosterol and 1-3 parts of glycylglycine.
According to the invention, after the Babylonia is transported, the drug preparation A containing florfenicol and sulfamethoxazole and the drug preparation B containing allicin, glucose oxidase, beta-sitosterol and glycylglycine are sequentially added, so that the agent A has a killing or certain inhibition effect on pathogenic bacteria; the agent B can simulate natural culture environment, is suitable for Babylonia, helps the Babylonia resist urgent reaction caused by environmental change, maintains organism activity, and reduces stress. Under the synergistic effect of the components, the Chinese medicinal composition can improve the curative effect, effectively inhibit bacteria, repair intestinal tracts, eliminate inflammation, reduce stress injury and improve the immunity function of the Babylonia body. The compound preparation has excellent treatment effect and blocking effect on the stress injury of the Babylonia after transportation, can obviously reduce the incidence rate of the stress injury of the Babylonia, can control the problem of the stress injury of the Babylonia and is not easy to relapse.
Preferably, the mass ratio of the agent A to the agent B is 2-5: 2.5 to 4. Further preferably, the mass ratio of the agent A to the agent B is 3.5-4.5: 3 to 4.
Preferably, the agent A comprises the following components in parts by weight: 12-15 parts of florfenicol and 10-12 parts of sulfamethoxazole; the agent B comprises the following components: 18-20 parts of allicin, 6-8 parts of glucose oxidase, 3-4 parts of beta-sitosterol and 2-3 parts of glycylglycine.
Furthermore, the invention claims a preparation method of a pharmaceutical preparation, which comprises the steps of uniformly mixing florfenicol and sulfamethoxazole to prepare an agent A; and uniformly mixing allicin, glucose oxidase, beta-sitosterol and glycylglycine to prepare the agent B.
Further, the invention claims the application of a pharmaceutical preparation in preparing a medicament for treating stress injury after transportation of Babylonia.
In the invention, the stress injury refers to that the Babylonia is not suitable for a new environment, and any one or more symptoms such as the weakness of the expansion of the gastropod or incapability of retracting into the shell, the swelling of the gastropod caused by water absorption, the red swelling of the anastomat tube, the upward gastropod or the recumbent spiral body, no ingestion or slow ingestion and the like appear successively, and finally death is caused.
Further, the invention claims a cultivation method of transported Babylonia, wherein the transported Babylonia is soaked by using the agent A, water is changed, and then the Babylonia is soaked by using the agent B; the agent A comprises the following components in parts by weight: 8-15 parts of florfenicol and 6-14 parts of sulfamethoxazole; the agent B comprises the following components: 10-20 parts of allicin, 5-8 parts of glucose oxidase, 2-4 parts of beta-sitosterol and 1-3 parts of glycylglycine.
Preferably, the soaking time of the agent A is 2-3 hours.
Preferably, the soaking time of the agent B is 1-2 hours.
Preferably, when the agent A and the agent B are applied, the water level of the pool is reduced to 10-15 cm away from the sand surface. At this level, oxygen can reach the level of the water that is pumped out. The waste of the medicine can be reduced by lowering the water level, and the oxygen can reach the degree of pumping out water, so that the oxygen deficiency caused by long-time oxygen stopping can be prevented; in addition, the medicine can be uniform, and the sediment is prevented from being deposited on the sand layer.
Preferably, the agent A and the agent B are used continuously for 3 to 4 days.
Specifically, the Babylonia is Babylonia genus (Babylonia) including, but not limited to, babylonia (Babylonia areolata), babylonia (lutosa), babylonia (Babylonia formosae), and the like.
Compared with the prior art, the invention has the following beneficial effects:
(1) The invention provides a pharmaceutical preparation, wherein an agent A and an agent B are adopted for matching, and the agent A has a killing or a certain inhibiting effect on pathogenic bacteria; the agent B can simulate a natural culture environment, is suitable for the Babylonia, helps the Babylonia resist urgent reaction caused by environmental change, maintains organism activity, and reduces stress; the invention can play a role in synergistically improving the drug effect by matching the agent A and the agent B, has excellent treatment effect on the stress injury of the Babylonia after transportation, and remarkably reduces the incidence rate of the stress injury of the Babylonia after transportation.
(2) The pharmaceutical preparation provided by the invention is green and safe, and has no toxicity, harm, side effect and adverse reaction to Babylonia.
Drawings
FIG. 1 is a schematic diagram of packaging and packing Babylonia, a Zhanjiang mud, into a foam box just captured from a culture pond.
Fig. 2 is a state diagram of the Babylonia which is a transport mud from Zhanjiang to Hainan and is put into a culture pond after being subjected to stress injury.
Fig. 3 is a diagram of dead Babylonia with stress injury.
Fig. 4 is a schematic field diagram of a treatment trial group of eastern whelk stress injury.
Fig. 5 is a state diagram of the first day of Babylonia after bath treatment in example 5.
FIG. 6 is a state diagram of Babylonia on the next day after bath treatment with the traditional Chinese medicine of example 5.
FIG. 7 is a state diagram of Babylonia on the third day after bath treatment in example 5.
Detailed Description
The invention is further illustrated in the following drawings and specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
Example 1A pharmaceutical formulation
A pharmaceutical formulation comprising an agent a and an agent B; the preparation method of the agent A comprises the following steps: and (3) uniformly mixing 12 parts of florfenicol and 10 parts of sulfamethoxazole according to parts by weight to obtain the agent A. The preparation method of the agent B comprises the following steps: and uniformly mixing 20 parts of allicin, 6 parts of glucose oxidase, 4 parts of beta-sitosterol and 2 parts of glycylglycine according to parts by weight to obtain the agent B.
EXAMPLE 2A pharmaceutical formulation
A pharmaceutical formulation comprising an agent a and an agent B; the preparation method of the agent A comprises the following steps: and (3) uniformly mixing 15 parts of florfenicol and 12 parts of sulfamethoxazole according to parts by weight to obtain the agent A. The preparation method of the agent B comprises the following steps: according to parts by weight, 18 parts of allicin, 8 parts of glucose oxidase, 3 parts of beta-sitosterol and 3 parts of glycylglycine are uniformly mixed to obtain the agent B.
EXAMPLE 3A pharmaceutical formulation
A pharmaceutical formulation comprising an agent a and an agent B; the preparation method of the agent A comprises the following steps: and (3) uniformly mixing 8 parts of florfenicol and 14 parts of sulfamethoxazole according to parts by weight to obtain the agent A. The preparation method of the agent B comprises the following steps: and uniformly mixing 10 parts of allicin, 8 parts of glucose oxidase, 4 parts of beta-sitosterol and 1 part of glycylglycine according to parts by weight to obtain the agent B.
EXAMPLE 4A pharmaceutical formulation
A pharmaceutical formulation comprising an agent a and an agent B; the preparation method of the agent A comprises the following steps: and (3) uniformly mixing 12 parts of florfenicol and 6 parts of sulfamethoxazole according to parts by weight to obtain the agent A. The preparation method of the agent B comprises the following steps: and (3) uniformly mixing 15 parts of allicin, 5 parts of glucose oxidase, 2 parts of beta-sitosterol and 2 parts of glycylglycine according to parts by weight to obtain the agent B.
EXAMPLE 5 therapeutic test of pharmaceutical formulations against Tonic stress injury
From Zhanjiang transportation of 128 jin of mud Babylonia to Hainan, the mud Babylonia reaches the Hainan with the specification of 35-40 g (shown in figure 1) and has the phenomena of stress injury and large-scale death of different degrees. Stress injury is manifested as: the eastern wind snail sequentially has symptoms of weak expansion of the gastropod or incapability of retracting into the shell, swelling of the gastropod due to water absorption, red and swollen kistrodon, upward gastropod or recumbent spiral body, no ingestion or slow ingestion, and the like, and finally causes death; in addition, some of the soft parts of the Babylonia are separated from the shells and ingested by other Babylonia to infect them, leaving empty shells and small spots with gastropod muscles (as shown in FIGS. 2 and 3).
And fishing out the mud Babylonia with stress injury, discarding, incinerating to prevent infection, and sterilizing the whole pond by povidone iodine. And (3) carrying out a grouping medicine test on mud snails which do not show symptoms (as shown in figure 4), fishing out 100 mud snails, placing the mud snails in a white test box, and paving fine sand with the diameter of 1-3 mm in the box for 2 hours to flow water. The mud Babylonia is soaked in a medicated bath by adopting the pharmaceutical preparation prepared in the embodiment 1, and the specific operation is as follows:
Firstly, the water supply valve of the water pipe of the test box is closed, the water adding is stopped, the drainer is opened, and the height of the water in the test box is reduced to a position where the bubble stone can throw out oxygen in a vertical state or the depth of 3-5 cm is suitable for submerging the spiral body of the Babylonia. In the morning, 40ppm (based on the volume of water in the test chamber) of the agent A prepared in example 1 was dissolved in clean seawater, and poured into the test chamber to soak Babylonia in the agent A, and after 3 hours, the water supply valve was opened to change water. The water level is reduced in the afternoon according to the operation method, 35ppm (based on the volume of water in the test box) of the agent B prepared in the example 1 is poured into the test box, so that the Babylonia is soaked in the agent B, the whole body of the screw body is bathed by the liquid medicine, the medicated bath is carried out for 2 hours, water is supplied and drained at the same time, and the water environment in the test box is kept clean.
The treatment period was 3 days (as shown in fig. 5, 6 and 7), and each of the doses a and B was administered once daily. The tours are patrolled for 3 times in the morning, in the middle and at the evening, and the eastern conch with stress injury symptoms are timely picked up and recorded. After one cycle of treatment, observations were continued for 4 months, and eastern whelk was no longer ill.
EXAMPLE 6 therapeutic test of pharmaceutical formulations against Tonic stress injury
The difference between this embodiment and embodiment 5 is that: the pharmaceutical formulation of example 2 was used.
EXAMPLE 7 therapeutic test of pharmaceutical formulations against Tonic stress injury
The difference between this embodiment and embodiment 5 is that: 50ppm of the pharmaceutical formulation A prepared in example 3 was used; 25ppm of pharmaceutical formulation B prepared in example 3 was used.
EXAMPLE 8 therapeutic test of pharmaceutical formulations against Tonic stress injury
The difference between this embodiment and embodiment 5 is that: 20ppm of the pharmaceutical formulation A prepared in example 4 was used; 40ppm of pharmaceutical formulation B prepared in example 4 was used.
Comparative example 1
The difference between this comparative example and example 5 is that: the pharmaceutical formulation of example 1 was not used in this comparative example.
Comparative example 2
The difference between this comparative example and example 5 is that: florfenicol was used in place of the agent A prepared in example 1.
Comparative example 3
The difference between this comparative example and example 5 is that: sulfamethoxazole was used in place of the agent A prepared in example 1.
Comparative example 4
The difference between this comparative example and example 5 is that: the agent B contains no allicin.
Comparative example 5
The difference between this comparative example and example 5 is that: the agent B contains no glucose oxidase.
Comparative example 6
The difference between this comparative example and example 5 is that: the agent B does not contain beta-sitosterol.
Comparative example 7
The difference between this comparative example and example 5 is that: the agent B does not contain glycylglycine.
Comparative example 8
The difference between this comparative example and example 5 is that: the agent A prepared in example 1 was replaced with amoxicillin soluble powder (source: guangzhou gold aquatic animal health products Co., ltd., trade name "Junpudi").
Comparative example 9
The difference between this comparative example and example 5 is that: the preparation A prepared in example 1 was replaced with neomycin sulfate powder (source: guangzhou gold aquatic animal health products Co., ltd., trade name "Chang Gankang").
Comparative example 10
The difference between this comparative example and example 5 is that: no agent a was used in this comparative example.
Comparative example 11
The difference between this comparative example and example 5 is that: no agent B was used in this comparative example.
Test example 1
The incidence of stress injury of Babylonia in examples 5 to 6 and comparative examples 1 to 11 was tested as follows:
Incidence of stress injury: the number of developed eastern conch within 3 days was compared to the total number of eastern conch in the test chamber.
Calculation formula of test data: incidence = number of screws/total number of screws in 3 days x 100%.
Judgment criteria for onset of stress injury: the phenomena of empty shell, telescopic and weak gastropod or incapability of retracting into the shell, swelling of the water absorption of the gastropod, red swelling of the anastomat tube, hardening of the gastropod, upward gastropod, turning over of a screw body, recumbent and the like are symptoms of stress injury.
The number of Babylonia in each test box was 100, and the test results of each set of examples and comparative examples are shown in Table 1.
TABLE 1
From the above examples 5 to 8, it is known that the pharmaceutical preparation provided by the invention has excellent therapeutic effect and blocking effect on the stress injury of the transported Babylonia after the transportation of the Babylonia by carrying out medicated bath treatment on the transported Babylonia, and can remarkably reduce the incidence of the stress injury of the Babylonia, and the incidence of the stress injury of the Babylonia is less than or equal to 7%.
From example 5 and comparative example 1, it is understood that the incidence of stress injury after transportation of Babylonia is as high as 95% without any measure.
From example 5, comparative example 2 and comparative example 3, it is understood that when the combination of florfenicol and sulfamethoxazole is adopted in the pharmaceutical preparation, the composition has excellent therapeutic effect and blocking effect on stress injury after transportation of Babylonia, and the incidence of stress injury of Babylonia can be remarkably reduced.
As is clear from examples 5 and comparative examples 4 to 7, it is difficult to achieve the technical effects of the present invention when a B-agent lacking any one of allicin, glucose oxidase, β -sitosterol and diglycerin is used.
From example 5, comparative example 8 and comparative example 9, it is known that florfenicol and sulfamethoxazole have excellent therapeutic effects on stress injury after transportation of Babylonia. While some conventional antimicrobial agents in the art have little therapeutic effect on the stress injury of Babylonia.
As is clear from examples 5, 10 and 11, the combination of the agent a and the agent B can synergistically enhance the efficacy of the drug, and the drug preparation provided by the invention has excellent therapeutic effect and blocking effect on stress injury after transportation of Babylonia.
The foregoing examples are illustrative only and serve to explain some features of the method of the invention. The claims that follow are intended to claim the broadest possible scope as conceivable and the embodiments presented herein are demonstrated for the applicant's true test results. It is, therefore, not the intention of the applicant that the appended claims be limited by the choice of examples illustrating the features of the invention. Some numerical ranges used in the claims also include sub-ranges within which variations in these ranges should also be construed as being covered by the appended claims where possible.
Claims (9)
1. A pharmaceutical preparation composition is characterized by comprising an agent A and an agent B which are matched for use; the A agent consists of 8-15 parts by weight of florfenicol and 6-14 parts by weight of sulfamethoxazole; the agent B consists of 10-20 parts of allicin, 5-8 parts of glucose oxidase, 2-4 parts of beta-sitosterol and 1-3 parts of glycylglycine; the mass ratio of the agent A to the agent B is 2-5: 2.5 to 4.
2. The pharmaceutical preparation composition according to claim 1, wherein the agent a consists of 12-15 parts by weight of florfenicol and 10-12 parts by weight of sulfamethoxazole; the agent B consists of 18-20 parts of allicin, 6-8 parts of glucose oxidase, 3-4 parts of beta-sitosterol and 2-3 parts of glycylglycine.
3. A process for preparing a pharmaceutical formulation composition according to claim 1 or 2, comprising the steps of: uniformly mixing florfenicol and sulfamethoxazole to prepare a preparation A; and uniformly mixing allicin, glucose oxidase, beta-sitosterol and glycylglycine to prepare the agent B.
4. Use of a pharmaceutical formulation composition according to claim 1 or 2 for the manufacture of a medicament for the prevention of stress injury after transportation of Babylonia.
5. A method for culturing transported Babylonia for the purpose of non-disease treatment, comprising the following steps: soaking transported Babylonia by using an agent A, changing water after soaking, and then soaking by using an agent B;
The A agent consists of 8-15 parts by weight of florfenicol and 6-14 parts by weight of sulfamethoxazole; the agent B consists of 10-20 parts of allicin, 5-8 parts of glucose oxidase, 2-4 parts of beta-sitosterol and 1-3 parts of glycylglycine; the mass ratio of the agent A to the agent B is 2-5: 2.5 to 4.
6. The method according to claim 5, wherein the time for immersing the agent A is 2 to 3 hours.
7. The method according to claim 5, wherein the time for immersing the agent B is 1 to 2 hours.
8. The culture method according to claim 5, wherein the pool water level is lowered to 10 to 15cm from the sand surface when the agent A and the agent B are used.
9. The culture method according to claim 5, wherein the agent A and the agent B are used continuously for 3 to 4 days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410194760.4A CN117752776B (en) | 2024-02-22 | 2024-02-22 | Pharmaceutical preparation and application thereof in preparation of drugs for treating stress injury of Babylonia after transportation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410194760.4A CN117752776B (en) | 2024-02-22 | 2024-02-22 | Pharmaceutical preparation and application thereof in preparation of drugs for treating stress injury of Babylonia after transportation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117752776A CN117752776A (en) | 2024-03-26 |
| CN117752776B true CN117752776B (en) | 2024-05-03 |
Family
ID=90314801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410194760.4A Active CN117752776B (en) | 2024-02-22 | 2024-02-22 | Pharmaceutical preparation and application thereof in preparation of drugs for treating stress injury of Babylonia after transportation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117752776B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118416093B (en) * | 2024-07-02 | 2024-09-24 | 广东海洋大学 | Composite pharmaceutical composition and method for transporting Babylonia living bodies |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8924968D0 (en) * | 1989-11-04 | 1989-12-28 | Lalvani K T | Compositions of some therapeutic advantage from fish and other aquatic animals combined with garlic including or excluding the garlic actice principle allicin |
| CN102524131A (en) * | 2012-01-20 | 2012-07-04 | 广东海洋大学 | Method for enriching vibrio phage and biologically preventing host bacteria |
| CN112608183A (en) * | 2020-12-18 | 2021-04-06 | 辽宁绿农宝现代农业科技有限公司 | Biological traditional Chinese medicine organic fertilizer function nutrient, fertilizer and fertilizer preparation method |
| CN114617088A (en) * | 2022-03-14 | 2022-06-14 | 海南金雨海洋产业发展有限公司 | Breeding method for improving immunity of Babylonia |
| CN117084204A (en) * | 2023-09-27 | 2023-11-21 | 广东海洋大学 | Buffer solution for improving hatching rate and survival rate of eastern conch oocysts and method for hatching eastern conch oocysts |
-
2024
- 2024-02-22 CN CN202410194760.4A patent/CN117752776B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8924968D0 (en) * | 1989-11-04 | 1989-12-28 | Lalvani K T | Compositions of some therapeutic advantage from fish and other aquatic animals combined with garlic including or excluding the garlic actice principle allicin |
| CN102524131A (en) * | 2012-01-20 | 2012-07-04 | 广东海洋大学 | Method for enriching vibrio phage and biologically preventing host bacteria |
| CN112608183A (en) * | 2020-12-18 | 2021-04-06 | 辽宁绿农宝现代农业科技有限公司 | Biological traditional Chinese medicine organic fertilizer function nutrient, fertilizer and fertilizer preparation method |
| CN114617088A (en) * | 2022-03-14 | 2022-06-14 | 海南金雨海洋产业发展有限公司 | Breeding method for improving immunity of Babylonia |
| CN117084204A (en) * | 2023-09-27 | 2023-11-21 | 广东海洋大学 | Buffer solution for improving hatching rate and survival rate of eastern conch oocysts and method for hatching eastern conch oocysts |
Non-Patent Citations (4)
| Title |
|---|
| 我国水产饲料添加剂行业状况剖析及鱼用高效去药残饲料添加剂研发;庄若飞;中国硕士学位论文电子期刊农业科技;20190515;第1-44页 * |
| 方斑东风螺吻管水肿病病原菌的初步研究;黄郁葱等;渔业现代化;20090820;第36卷(第04期);第37-41页 * |
| 方斑东风螺肉壳分离病的防治方法;王国福等;河北渔业;20080820(第08期);第37-40页 * |
| 湖北部分地区大宗鱼类养殖用药调查与分析;温周瑞等;养殖与饲料;20170301(第03期);第12-15页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117752776A (en) | 2024-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117752776B (en) | Pharmaceutical preparation and application thereof in preparation of drugs for treating stress injury of Babylonia after transportation | |
| US20210137915A1 (en) | Pharmaceutical use and pharmaceutical composition of pyrroloquinoline quinine, its derivatives and/or its salts | |
| CN103005168A (en) | Microbial lysozyme microcapsule as well as preparation and application of microbial lysozyme microcapsule | |
| CN110178973A (en) | A kind of pharmaceutical chemistry additive for preventing and treating litopenaeus vannamei liver sausage born of the same parents worm | |
| CN102177868A (en) | Method for pond three-dimensional (3D) culture of Chinese prawns | |
| CN1762460A (en) | The Chinese herbal medicine compound prescription of control seawater fish shield balantidiasis | |
| CN108077331A (en) | A kind of preparation method and applications of synthesis detoxicating liquid used for aquiculture | |
| CN104920260B (en) | A kind of cultural method of selenium-rich Portunus trituberculatus Miers | |
| CN1632105A (en) | Bacillus subtilis preparation | |
| CN105125707A (en) | Plant extraction preparation for protecting liver and invigorating intestines in culturing of penaeus monodon and application of plant extraction preparation | |
| CN109385406A (en) | One plant of vibrio parahaemolyticus phage and its application in terms of enhancing aquatic livestock immunity | |
| JPH013127A (en) | Prevention and treatment of diseases of aquatic organisms | |
| CN102027883B (en) | Energy-saving type sea cucumber culturing method | |
| CN107812002A (en) | It is a kind of to be used for ornamental fish bacterium, virus, the medicine of parasite complex treatment | |
| CN109568464B (en) | Composition for preventing and treating shrimp and crab sporozoosis and application thereof | |
| CN105267237B (en) | A kind of compound formulation for being used to treat large yellow croaker stimulation cryptocaryoniosis | |
| CN117618450B (en) | Medicine additive, preparation method thereof and application thereof in preventing and treating Babylonia syndrome | |
| CN107372224A (en) | A kind of cultural method for improving Changchun bream survival rate | |
| CN109197700A (en) | A kind of prevention and treatment lime worm attachment Abalone breeding pool and the prescription and application method of young Bao | |
| CN117751875B (en) | Land-based ecological breeding method for Babylonia and application thereof | |
| CN111760032B (en) | Composition for preventing and treating drug-resistant coccidiosis of chicken and preparation method and application thereof | |
| CN108992448B (en) | Salt-containing degerming tablet for aquarium fish and preparation method thereof | |
| KR100451906B1 (en) | A remedy for prevention against fish disease, reinforcement of immune vitality and promotion of growth in a fish farm based on active component of chitosan and oligosaccharide | |
| CN105062915A (en) | Microecological preparation for degrading N and P (nitrogen and phosphorus) | |
| Nakajima | Epigenetic Activation of Animals, Fish, Crustaceans, Mollusks, and Plants by Administration of Dimethylsulfoniopropionate in Green Sea Algae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |